Aparna Srinivasa Babu MD, Presenter: Nothing to Disclose

Aliaksei Salei MD, Abstract Co-Author: Nothing to Disclose

Oleg Teytelboym MD, Abstract Co-Author: Nothing to Disclose

• Review currently available bone targeted radiopharmaceuticals • Review newly available Radium-223 therapy for prostate cancer metastasis • Describe indications and contraindications for use of bone targeted radiopharmaceuticals • Review Nuclear Regulatory Commission (NRC) guidelines and radiation safety involved in treatment with radiopharmaceuticals  

After a brief introduction to osseous metastasis, including its pathophysiology, we will offer examples of appearance of osseous metastases on different imaging modalities. Detailed discussion of bone radiopharmaceuticals will include mechanisms of action, expected outcomes, indications and contraindications for therapy, dosage and administration guidelines. We will review precautions, directions for storage and handling, patient instructions and follow-up recommendations. We will provide insight into intricacies of setting up a multidisciplinary treatment program and optimizing patient selection. We will delve into the advantages and disadvantages of currently available treatment options, with specific emphasis on the newly available Radium-223 therapy. We will examine major past and ongoing trials in this regard. Finally, we will present a comprehensive summary of various aspects of treatment of osseous metastases using bone radiopharmaceuticals.  

http://abstract.rsna.org/uploads/2014/14016480/14016480_ck2f.pdf

Srinivasa Babu, A, Salei, A, Teytelboym, O, Bone Radiopharmaceuticals: What Radiologists Need to Know.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14016480.html